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Abstract
Purpose Glycogen synthase kinase 3 (GSK3) is a key controlling element of many cellular processes including cell-cycle 
progression and recent studies suggest that GSK3 is a potential anticancer target. Changes in glucose metabolism associ-
ated with GSK3 inhibition may impact on lipid synthesis, whilst lipid metabolites can act as molecular response markers.
Methods Here, SKBr3 breast and HCT8 colorectal cancer cells were treated with the GSK3 inhibitor SB216763, and  [14C 
(U)] glucose and  [3H] choline incorporation into lipids was determined. Cell extracts from treated cells were subject to 31P 
NMR spectroscopy.
Results SB216763 treatment decreased choline incorporation into lipids and caused an accumulation of CDP-choline which 
was accompanied by decreased conversion of glucose into lipid components.
Conclusion SB216763 profoundly inhibits phospholipid synthesis in cancer cells which demonstrate accumulation of CDP-
choline detectable by 31P NMR spectroscopy. Metabolic changes in lipid metabolism present potential response markers to 
drugs targeting GSK3.
Keywords Glycogen synthase kinase 3 · CDP-choline · 31P nuclear magnetic resonance spectroscopy · Lipid · Glucose · 
Choline
Introduction
Glycogen synthase kinase 3 (GSK3) is a family of serine/
threonine kinases comprising GSK3α and GSK3β which was 
originally identified as a key controller of metabolism via its 
inhibitory phosphorylation of glycogen synthase [1]. More 
recently, GSK3 has been shown to control a broad range of 
cellular functions through phosphorylation of many target 
proteins [2]. These functions include cell-cycle progression, 
energy homeostasis and inflammation [2]. GSK3 activity is 
constitutively activated and control of its activity is chiefly 
through inhibitory phosphorylation of serine-9. One major 
pathway responsible for this inhibition is the PI3K/PDK1/
Akt pathway [3] which is frequently up-regulated in can-
cer and controls glucose metabolism [4]. Abnormal GSK3 
activity is associated with several disease states including 
diabetes, inflammation and cancer [5]. It has been proposed 
that GSK3 could be a target for anticancer treatments [6] 
and studies have shown that inhibition of GSK3 activity is 
associated with suppressed cancer growth, and in breast and 
colorectal cancer, it can attenuate resistance to anticancer 
treatments [7]. Inhibition of GSK3 in glioma has been shown 
to induce cell death preceded by changes in glucose metabo-
lism including reduced glucose content [8].
Cancer is associated with increased phospholipid metabo-
lism due to high demand for membrane synthesis and intra-
cellular signalling. 31P NMR spectroscopy is an analytical 
technique which facilitates quantitation of phosphorus-con-
taining molecules in cells, tissues and their extracts [9, 10]. 
The technique is clinically translatable and patient studies of 
cancer tissue in vivo and subsequent analysis of extracts of 
the tumour have demonstrated high levels of the phosphati-
dylcholine metabolite phosphocholine (PCho) [11] which 
decrease in cancers responding to treatment [12].
As phospholipid synthesis requires intermediates from 
glucose metabolism, we hypothesised that inhibition of 
GSK3 may result in changes in phospholipid metabolite con-
tent that may be evident in using 31P NMR. To investigate 
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this, we have subjected chemical extracts from cancer cells 
treated with growth inhibitory doses of the GSK3 inhibitor 
SB216763 to 31P NMR spectroscopy.
Methods
Materials
Unless otherwise stated, all chemicals were purchased from 
Sigma-Aldrich (Poole Dorset). Cancer cell lines were pur-
chased from ATCC (LGC Standards, Teddington, UK) and 
maintained in Dulbecco’s Modified Eagles medium (Gibco, 
Life Technologies ltd, UK) supplemented with 10% foe-
tal bovine serum and penicillin (100µU/ml)/streptomycin 
(100 µg/ml) in 75 cm2 tissue culture flasks until confluent. 
MDA-MB-468 breast cancer cells and HCT-8 colorectal 
cancer cells were obtained from the American Tissue Cul-
ture Collection (ATCC) (LGC standards UK).
Cytotoxicity assay
The sensitivity of cancer cells to the GSK3 inhibitor 
SB216763 was determined using the MTT [(3-(4,5-Dimeth-
ylthiazol-2-yl)-2,5-Diphenyltetrazonium Bromide] assay. 
Briefly, cells were seeded in 96-well plates by adding 
100 µl of cells per well at cell densities of 5 × 104 per ml. 
The cells were left overnight at 37 °C in a  CO2 incubator, 
and then treated with a range of concentrations of SB216763 
(1–200 µM) for 72 h. Cells were then quantified by addi-
tion of MTT (0.5 mg/ml in medium) and incubation for 2 h 
followed by removal of medium and addition of DMSO 
(200 µl). The absorbance was then measured at 570 nm 
using a scanning multi-well spectrophotometer (Dynatech 
MR 5000, Dynatech Laboratories, Chantilly,VA, USA) 
after 10-s agitation and the readings analysed using Ascent 
software.  IC50s were calculated using CompuSyn software 
(ComboSyn, Paramus, NJ, USA).
[3H‑methyl]Choline incorporation assay
Cells  (106) in 5 ml of medium were seeded in eight 25 cm2 
tissue culture flasks and left overnight in a  CO2 incuba-
tor at 37 °C. The cells were then treated for 4, 24 or 72 h 
with SB216763 (40  µM) after which the medium was 
removed and fresh media (0.5 ml) containing 37KBq/ml of 
 [3H-methyl] choline were added and incubated at 37 °C for 
15 min. The cells were then washed 4 × by the rapid rins-
ing of each flask with ice-cold phosphate-buffered saline 
(5 ml). The cells were then incubated with medium (1 ml) 
for 1 h at 37 °C after which the medium was retained for 
measurement of radioactivity and the cells detached and 
transferred into a microfuge tube. The cells were pelleted by 
centrifuging at 400g for 5 min and the supernatant retained 
for radioactive counting. The cells were then lysed by addi-
tion of 0.375 ml of a 1:2 mixture of chloroform and metha-
nol, and periodic agitation on a vortex mixer for 1 h. Then, 
0.125 ml of TRIS: HCl buffer (1 mM pH 7.4) and 125 ml 
of chloroform were added. After shaking the mixture was 
centrifuged at 10,000g for 10 min and the upper (aqueous 
phase) and lower (lipid phase) were collected. The cell resi-
due at the interface was dissolved in 0.5 ml of NaOH (1 M) 
and after neutralising with HCl (1 M) the protein content in 
the cell residue determined. The lipid phase was added to 
scintillation fluid (5 ml). The volume of the aqueous phase 
was determined and 100 µl was added to a scintillation vial 
containing 5 ml of scintillation fluid. A further 100 µl was 
subject to phosphate precipitation [13] by addition of 100 µl 
each of Ba(OH)2 (0.3 M) and  ZnSO4 (5%) followed by vig-
orous shaking for 5 min. The precipitate was pelleted and 
150 µl was added to a scintillation vial with 5 ml of scintil-
lation fluid.
[U‑14C]Glucose incorporation into lipids and glycerol 
assay
As described previously [14], cells were prepared as for 
‘[3H] choline incorporation assay’ and cells were incubated 
with  [14C-U] glucose in medium (0.5 ml) (3.7 KBq/ml) for 
2 h. The cells were then washed 4 × with ice-cold PBS, 
detached with trypsin and transferred to a 1-ml microfuge 
tube and pelleted by centrifugation at 400g for 5 min. The 
supernatant was removed and radioactivity was determined 
by adding to a scintillation vial containing 5 ml of scintil-
lation fluid and measuring in a scintillation counter. The 
pelleted cells were suspended in PBS (1 ml), pelleted and 
radioactivity determined in the wash. The lipid and aque-
ous components were then fractionated as described for 
‘[3H-methyl] choline incorporation assay’. The lipid phase 
volume was measured and radioactivity determined in a 
50-µl sample. The remainder was dried at 37 °C and the 
complex glycerides were subject to saponification by dis-
solving in a 1:10 water: ethanol solution of KOH (10 M) 
and heating to 70 °C for 20 min [15]. The glycerol and fatty 
acids were separated by fractionation into aqueous and lipid 
phases as described above [16] and the radioactivity was 
determined in the two phases.
NMR sample preparation and 31P NMR spectroscopy
Cells (2 ×  106) were seeded in each of four 75 cm2 tissue 
culture flasks and allowed to achieve 80% confluence in a 
 CO2 incubator at 37 °C. Media were then removed and 10 ml 
of medium containing SB216763 (40 µM) was added to 2 
flasks and 10 ml of medium containing the same volume 
of DMSO (vehicle—typically 10 µl) was added to the two 
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control flasks. After the respective treatment period (24 or 
72 h), the cells were detached with trypsin (5 ml) and the 
trypsin neutralised with ice-cold medium decanted into 
15 ml tubes and placed on ice for 10 min. The cells were 
then centrifuged at 400g for 5 min and after removal of the 
medium, the cells were suspended in ice-cold saline (0.9%) 
(1 ml) transferred to a microfuge tube, centrifuged at 400g 
for 5 min. This step was repeated twice to remove extra-
cellular phosphate. The pellet was suspended in 0.375 ml 
of chloroform: methanol (1:2) and 10 µl EDTA (10 mM) 
and 20 μl of 1-aminopropyl phosphoric acid (0.3 µmol) as 
an internal standard and left on ice for 1 h with occasional 
mixing. The aqueous and lipid phases were then separated 
by addition of 125 ml each of chloroform and TRIS buffer 
(10 mM pH7.4) followed by centrifugation at 12,000g for 
10 min. The aqueous phase was then made up to 0.6 ml by 
addition of 60 µl of  D2O and water. The NMR measure-
ment was carried out on a Bruker ADVANCE III 400 NMR 
spectrometer (400 MHz) operating at 161.98 MHz for 31P 
with continuous broadband 1H decoupling (WALTZ16) and 
at least 20,000 acquisitions. The parameters for each acqui-
sition were: acquisition time 1.258 s; relaxation delay 2 s 
(inter-pulse time = 3.258 s) (metabolite concentrations were 
the same when spectra were obtained with a 1-s relaxation 
delay, indicating that metabolites were fully relaxed in this 
solvent system after a 1-s delay [17]); pulse angle 45°. All 
acquisitions were made at 25 °C. Metabolite concentrations 
were determined by comparison with the internal standard 
(0.3 µmol) signal at 11.8 ppm. The reference for 0 ppm is 
85%  H3PO4.
Glycogen synthesis
Cells were seeded  (106 per flask) in 25 cm2 flasks, then 
treated in triplicate when 70% confluent with SB216763. 
Glycogen synthesis was assessed by measuring conversion 
of  [14C-(U)]-glucose into  [14C-(U)]-glycogen in the cells 
treated with SB216763 for 4 h. The cells were incubated 
with 0.25 ml of  [14C]-glucose (55 KBq/ml) for 90 min, 
washed rapidly with ice-cold PBS, then dissolved in 150 µl 
of KOH 20% (w/v) for 1 h at 70 °C. Glycogen was precipi-
tated by addition of 50 µl of glycogen (2 mg/ml) as carrier 
followed by 0.5 ml of ice-cold ethanol and leaving for 2 h 
at − 20 °C. After centrifugation at 10,000g for 10 min, the 
supernatant was removed, and the precipitated glycogen dis-
solved in 150 µl of hot water, and transferred to scintillation 
vials containing 5 ml of scintillation fluid. The radioactive 
glycogen value was normalised to protein content carried 
out on 50 µl of the supernatant after neutralising the KOH 
with HCl (1 M).
Statistics
Data are expressed as mean ± SEM and statistical differ-
ences determined by the student t test and values expressed 
as (t = x, p < y), where t values and probability are unitless 
values. All experiments were carried out 2 or more times.
Results
Cancer cell sensitivity to SB216763
The effect of 3-day treatment with different concentrations 
of SB216763 (0–100 µM) on the growth of SKBr3 cells is 
shown in Fig. 1. Subsequent experiments were carried out 
using 40 µM concentrations of SB213673.
Changes in 31P NMR detectable metabolites 
by SB216763 treatment
Control cells and cells treated with SB216763 were subject 
to 31P NMR spectroscopy. Figure 2a–c shows an example 
of 31P NMR spectra from a chemical extract of control and 
SB216763-treated SKBr3 cells. A peak corresponding with 
CDP-choline which was at very low levels or undetectable 
levels in the controls was present at significantly higher 
levels (p < 0.05) in the cells treated with SB216763 for 
24 h [control 0.002 µmol/mg protein (± 0.001), SB-treated 
0.012 µmol/mg protein (± 0.003)] and was also present in 
cells treated for 72 h (Fig. 2c). The CDP-choline peak was 
also present in HCT8 colorectal cancer cells treated with 
SB216763 for 24 h (Fig. 2e) but not controls (Fig. 2d). CDP-
choline is formed by reaction of phosphocholine (PCho) 
with cytidine triphosphate (CTP). The content of PCho was 
similar in control [0.1 (± 0.012) µmol/mg protein] and SB-
treated [0.085 (± 0.03) µmole/mg protein] SKBr3 cells. The 
next step is the reaction of CDP-choline with diacylglycerol 
(DAG). As DAG can be formed, de novo, from the glycolysis 
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Fig. 1  Relative growth of SKBr3 cells treated with doses of 
0–100 µM SB216763 for 3 days
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intermediate glycerol 3 phosphate, the effect of SB216763 
on carbon flux from glucose was examined.
Flux of  [14C] from glucose to lipids
Glucose incorporation into lipids was determined in SKBr3 
and HCT8 cells. Figure 3 shows the incorporation of glucose 
into lipid (Fig. 3a) and fatty acids (Fig. 3b) and glycerol 
(a)
(b)
(C)
CDP-choline
A                                B  C     D   E         F                 G            H  I      J                           K 
Fig. 2  31P NMR spectra from extracts of untreated  SKBr3 cells (a) or 
treated with SB216763 24 h (b) or 72 h (c) and untreated HCT8 cells 
(d) or treated with SB216763 for 24 h (e). Identities of metabolites 
are shown in Spectrum b (A: AMPA (standard), B: PCho, C: inor-
ganic phosphate D: GPE and GPC (two small peaks) E: Phosphocre-
atine F: γATP G: αATP H: nicotinamide adenine dinucleotide (NAD 
species) I: CDP-choline J: NAD species K: βATP
231Magnetic Resonance Materials in Physics, Biology and Medicine (2019) 32:227–235 
1 3
(Fig. 3c) in cells treated with SB216763 relative to untreated 
cells. In both cell lines, the incorporation of 14C- from glu-
cose into lipid was decreased (SKBr3: t = 11.7, p < 0.001; 
HCT8 t = 8.2, p < 0.001) and this decrease was found to be 
in both the glycerol (derived from dihydroxyacetone phos-
phate during glycolysis) (SKBr3: t = 3.1, p < 0.01; HCT8: 
7.3, p < 0.001) and fatty acid (derived from intermediates of 
the Krebs cycle) (SKBr3: t = 11, p < 0.001; HCT8: t = 9.3, 
p < 0.001) fractions.
Effect of SB216763 treatment on choline uptake 
and incorporation into lipids
Figure 4 shows the total uptake (a and b) and proportion 
of phosphorylated  [3H-methyl] choline (c and d) and the 
incorporation into lipids (e and f) by SKBr3 and HCT8 
cells treated with SB216763 for 4, 24 and 72 h compared 
with untreated cells. In each cell line,  [3H-methyl] choline 
incorporation into lipids was decreased after 4 h (HCT8: 
t = 5.6, p < 0.001; SKBr3: t = 16, p < 0.001), 24 h (HCT8: 
t = 5.8, p < 0.001; t = 3.5, p < 0.01) and 72  h (HCT8: 
t = 6.6, p < 0.001; SKBr3: t = 28, p < 0.001) treatment with 
SB216763. The uptake of  [3H-methyl] choline was unaf-
fected by treatment of cells with SB216763 by each cell line 
at each time point except HCT8 cells at 72 h which showed 
a significant (t = 3.3 p < 0.05) increase in incorporation. 
The proportion of  [3H-methyl] choline that was phospho-
rylated was unchanged in cells treated for 4 h, decreased in 
HCT8 (t = 4.1, p < 0.01) and SKBr3 (t = 18 p < 0.001) cells 
treated for 24 h and unchanged in cells treated for 72 h with 
SB216763.
The effect of treatment with SB216763 on glycogen syn-
thesis cells is shown in Fig. 5. Conversion of  [14C] glucose 
into  [14C] glycogen was found to be increased by HCT8 cells 
treated with SB216763.
(d) 
(e)
CDP-choline
Fig. 2  (continued)
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Discussion
De novo synthesis from glucose is the major route for the 
formation of diacylglycerol (DAG) for metabolic purposes 
[18]. The flux of carbon from glucose into anabolic path-
ways responsible for the synthesis of phospholipids is facili-
tated in cancer cells by decreased oxidative phosphorylation 
and increased glycolysis resulting in an increased supply of 
acetyl CoA for glycerol and fatty acid synthesis [19].
Phospholipid metabolism is crucial for proliferation as 
it provides cell membrane and intracellular signalling com-
ponents [20]. Phosphatidylcholine (PtdCho) is an abundant 
phospholipid in mammalian cell membranes [21] and is an 
important source of intracellular signalling pathway inter-
mediates [22]. Inhibition of PtdCho synthesis in mammalian 
cells including cancer has been shown to induce cell death 
[23]. The de novo synthesis of PtdCho occurs by the CDP-
choline pathway. Choline, taken into cells by the choline 
transporter (ChT), is phosphorylated to phosphocholine 
(PCho) by choline kinase. The enzyme CTP phosphocho-
line cytidylyltransferase (CT) converts Cytidine triphos-
phate (CTP) and PCho into CDP-choline. The enzyme 
CDP-choline:1,2-diacylglycerolcholinephosphotransferase 
(CPT) then catalyses the conversion of CDP-choline and 
diacylglycerol into PtdCho.
Breast cancer cells were found to be sensitive to the 
growth inhibitory effect of the GSK3 inhibitor SB216763 in 
agreement with others [24]. Zeng et al. [25] have shown that 
overexpression of GSK3β in non-small-cell lung cancer is 
associated with poor prognosis and its inhibition decreased 
cell proliferation by causing cell-cycle arrest in G1/S. They 
suggested that GSK3β acts as a tumour promoter and a 
potential therapeutic target. Evidence from work on MCF7 
breast cancer cells suggests that the growth inhibitory effect 
of GSK3β inhibition results subsequent decrease in cyclin 
D1 expression [26].
Treatment of SKBr3 and HCT8 cells with S216763 
decreased the flux of carbon from glucose to lipids and the 
incorporation of choline into lipids which could be attributed 
to increased formation of glycogen from glucose associated 
with GSK3β inhibition [27]. In agreement with these find-
ings Park et al. [28] has recently shown that inhibition of 
GSK3β in colorectal cancer cells resulted in decreased fatty 
acid synthesis.
31P NMR studies were carried out on cells treated for 
up to 72 h with SB216763 in common with previous work 
[29]. Interestingly, CDP-choline formation is considered as 
the rate-limiting step for PtdCho formation; so, its build up 
is unusual further suggesting that the decrease in PtdCho in 
cells treated with SB216763 formation is a consequence of 
inadequate substrate (DAG) for the final CTP-catalysed reac-
tion of CDP-choline and DAG. Anthony et al. [30] has dem-
onstrated that several drugs induce the cellular build-up of 
CDP-choline. These drugs included farnesol and cheleryth-
rine which directly inhibit CDP-choline:1,2-diacylglycerol 
cholinephosphotransferase. They also found that camptoth-
ecin and etoposide, which are inhibitors of phosphokinase 
C and induce apoptosis, also increase CDP-choline accumu-
lation which they attributed to indirect inhibition of CDP-
choline:1,2-diacylglycerol cholinephosphotransferase by pH 
shifts during the apoptotic process. The mechanism for the 
appearance of CDP-choline in SB216763-treated cells has 
yet to be fully elucidated but may be a result of  less glucose 
being utilised in the formation of phospholipid intermediates 
via glycolysis.
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Fig. 3  Incorporation of 14C into lipid-soluble metabolites (fraction of 
total  [14C] glucose uptake) (a) and fraction of lipid-soluble 14C incor-
porated into Fatty acids (b) and glycerol (c) untreated and SB216763-
treated SKBr3 and HCT8 cells. Cells were incubated with  [14C (U)] 
glucose for 2  h then washed rapidly with ice-cold PBS. Cells were 
fractionated into aqueous and lipid soluble components and 14C-asso-
ciated with the lipid fraction determined (a). The lipid fraction was 
subject to saponification to release the fatty acids from glycerol and 
then fractionated into lipid (fatty acids) (control (grey) SB216763-
treated (grey)) and aqueous (glycerol) (control (white) SB216763-
treated (grey)) and 14C-associated with the two fractions determined
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Previous studies [12, 31] have shown that the content of 
PMEs decrease in tumours responding to treatment and that 
this may be a useful early response indicator. Although treat-
ment of cancer cells with SB216763 was not accompanied by 
changes in the concentration of PCho, the appearance of the 
CDP-choline peak in the 31P NMR spectrum suggests that 
this might be a useful early indicator of response to drugs 
targeting GSKβ. However, early expectations that in vivo 31P 
NMR spectroscopy could be used in the clinic have not yet 
materialised, mainly due to the relative insensitivity of the 
technique compared with, for example  [18F]-FDG-PET. A 
further problem with the quantification of the CDP-choline 
resonance in in vivo spectra is its chemical shift, which is 
close to that of nucleotide adenine.dinucleotide (NAD(H)) 
resonance with which it most likely forms a composite peak. 
On a more positive note, instruments with higher magnetic 
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Fig. 5  Incorporation of  [14C] into glycogen by control and 
SB216763-treated HCT8 cells incubated with  [14C] glucose
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field strengths and proton decoupling are improving peak 
resolution [32].
In conclusion, treatment of cancer cells with the GSK3 
inhibitor SB216763 results in decreased transfer of carbon 
from glucose to lipids, cellular accumulation of CDP-choline 
and decreased incorporation of choline into PtdCho.
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